Abstract
Birch bark extract (Filsuvez®; also known as the developmental name Oleogel-S10), a topical gel consisting of 10% dry birch bark extract and 90% sunflower oil, is the first therapy approved in the EU and UK for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients aged ≥ 6 months old. In the pivotal double-blind, randomized, vehicle-controlled, phase III EASE trial in patients with EB, the primary endpoint was met, in which birch bark extract relative to control gel significantly increased the proportion of patients with first complete target wound closure within 45 days. Moreover, patients treated with birch bark extract demonstrated several other positive findings in improving wound burden and wound-associated symptoms. The clinical benefits of birch bark extract were maintained in the 24-month open-label extension period of the EASE trial. Birch bark extract was generally well tolerated in patients with EB, with the tolerability profile being similar to that of control gel. Current evidence indicates that birch bark extract is an effective, emerging treatment option for patients with dystrophic and junctional EB.
Plain Language Summary
Epidermolysis bullosa (EB) is a rare, heterogenous genetic disorder characterized by extreme skin fragility and trauma-induced blister formation of the skin, mucosa or internal epithelial linings of organs. Due to lack of disease-modifying therapies, the mainstay treatment options for EB remain supportive in nature, such as wound care, skin protection, itch and pain management, infection control and trauma prevention. With various therapies being investigated as a potential treatment option for EB, birch bark extract (Filsuvez®; also known as the developmental name Oleogel-S10) topical gel has been approved in the EU and UK for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients aged ≥ 6 months old. Birch bark extract has demonstrated anti-inflammatory, antibacterial, antiviral, antimycotic and wound-healing properties. In patients with EB, birch bark extract relative to control gel significantly accelerated wound healing within 45 days, together with other positive findings in improving wound burden and wound-associated symptoms. The clinical benefits of birch bark extract in improving wound burden were maintained for up to 24 months of continued treatment. Birch bark extract was generally well tolerated in patients with EB, with most adverse events being mild to moderate in severity. Current evidence indicates that birch bark extract is an effective, emerging treatment option for patients with dystrophic and junctional EB.
Similar content being viewed by others
Change history
21 September 2023
A Correction to this paper has been published: https://doi.org/10.1007/s40265-023-01949-7
References
Bruckner-Tuderman L. Newer treatment modalities in epidermolysis bullosa. Indian Dermatol Online J. 2019;10(3):244–50.
Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.
EB Research Network. EB research network: understanding EB & its classification. 2022. https://www.eb-researchnetwork.org/research/what-is-eb/. Accessed 2 Aug 2023.
Wounds International. Best practice guidelines for skin and wound care in epidermolysis bullosa. An international consensus. 2017. https://ern-skin.eu/wp-content/uploads/2020/08/Skin-and-wound-care-EB.pdf. Accessed 2 Aug 2023.
Tang JY, Marinkovich MP, Lucas E, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1):175.
Bourrat E, Taieb C, Marquié A, et al. Burden of caregivers and out-of-pocket expenditures related to epidermolysis bullosa in France. J Eur Acad Dermatol Venereol. 2022;37(1):194–203.
Martin K, Geuens S, Asche JK, et al. Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines. Orphanet J Rare Dis. 2019;14(1):133.
Sumeray M. Development of two topical approaches to wound healing in EB—an update on progress with Oleogel-S10 and AP103 [abstract no. OP81 plus presentation]. Acta Derm Venereal. 2020;100(Suppl. 220):22.
European Medicines Agency. Filsuvez gel (birch bark extract): EU prescribing information. 2022. https://www.ema.europa.eu/. Accessed 2 Aug 2023.
Medicines & Healthcare products Regulatory Agency. Filsuvez gel (birch bark extract): UK prescribing information. 2022. https://products.mhra.gov.uk/. Accessed 2 Aug 2023.
Ebeling S, Naumann K, Pollok S, et al. From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract. PLoS ONE. 2014;9(1): e86147.
Schwieger-Briel A, Ott H, Kiritsi D, et al. Mechanism of Oleogel-S10: a triterpene preparation for the treatment of epidermolysis bullosa. Dermatol Ther. 2019;32(4): e12983.
Woelfle U, Laszczyk MN, Kraus M, et al. Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Investig Dermatol. 2010;130(1):113–23.
Wardecki T, Werner P, Thomas M, et al. Influence of birch bark triterpenes on keratinocytes and fibroblasts from diabetic and nondiabetic donors. J Nat Prod. 2016;79(4):1112–23.
Scheffler A. The wound healing properties of betulin from birch bark from bench to bedside. Planta Med. 2019;85(7):524–7.
Schwieger-Briel A, Kiritsi D, Schempp C, et al. Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study. Dermatol Res Pract. 2017;2017:5068969.
Gewert S, Kiritsi D, Schumann H, et al. Oleogel-S10 for the treatment of epidermolysis bullosa (EB)—a 4-patient case series [abstract no. P125]. Acta Derm Venereal. 2020;100(Suppl. 220):75–6.
Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa—results from the phase 3, randomised, double-blind phase of the ‘EASE’ study. Br J Dermatol. 2023;188:12–21.
Kern JS, Schwieger-Briel A, Löwe S, et al. Oleogel-S10 phase 3 study “EASE” for epidermolysis bullosa: study design and rationale. Trials. 2019;20(350):1–13.
Murrell DF, Bruckner A, Sprecher E, et al. Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study [abstract no. BG04]. Br J Dermatol. 2023;188(Suppl. 4):ljad113.44.
Food and Drug Administration. Epidermolysis bullosa: develo** drugs for treatment of cutaneous manifestations—guidance for industry. 2019. https://www.fda.gov/. Accessed 2 Aug 2023.
Jain SV, Harris AG, Su JC, et al. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2017;31(4):692–8.
Murrell DF, Bruckner A, Davis C, et al. Correlation between wound burden and procedural pain in patients with EB ≥4 years of age: an exploratory analysis from the EASE study [abstract no. 34650 plus poster]. J Am Acad Dermatol. 2022;87(3 Suppl.):AB152.
Kiritsi D, Murrell DF, Sprecher E, et al. EASE study demonstrates efficacy of Oleogel-S10 (birch triterpenes) on wound healing and pain in the pediatric epidermolysis bullosa population [abstract no. O012]. Pediatr Dermatol. 2022;39(Suppl. 1):9.
National Institute for Health and Care Excellence. Birch bark extract for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa [ID1505]. 2023. https://www.nice.org.uk/guidance/indevelopment/gid-ta10654. Accessed 2 Aug 2023.
Torres-Pradilla M, Álvarez E, Novoa M, et al. Oleogel-S10 (birch bark extract) in dystrophic epidermolysis bullosa: a case series evaluating the impact on wound burden over 2 years [abstract no. LB1791]. J Investig Dermatol. 2023;143(9):B34.
Acknowledgements
During the peer review process, the manufacturer of birch bark extract was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
Young-A Heo is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
The manuscript was reviewed by: M. Ågren Department of Dermatology & Copenhagen Wound Healing Center and Digestive Disease Center, Bispebjerg Hospital/Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; G. Yosipovitch, Dr Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Heo, YA. Birch Bark Extract: A Review in Epidermolysis Bullosa. Drugs 83, 1309–1314 (2023). https://doi.org/10.1007/s40265-023-01935-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01935-z